MX2019004862A - Anticuerpos anti-rankl y usos de los mismos. - Google Patents

Anticuerpos anti-rankl y usos de los mismos.

Info

Publication number
MX2019004862A
MX2019004862A MX2019004862A MX2019004862A MX2019004862A MX 2019004862 A MX2019004862 A MX 2019004862A MX 2019004862 A MX2019004862 A MX 2019004862A MX 2019004862 A MX2019004862 A MX 2019004862A MX 2019004862 A MX2019004862 A MX 2019004862A
Authority
MX
Mexico
Prior art keywords
antibodies
rankl antibodies
ligand
bone
cancer
Prior art date
Application number
MX2019004862A
Other languages
English (en)
Inventor
Ihor Korytko Andrew
H Obungu Victor
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2019004862A publication Critical patent/MX2019004862A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Rheumatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan anticuerpos y métodos para usar estos anticuerpos que se unen al activador de receptor de humano y ratón del ligando de factor nuclear kappa-B, dichos anticuerpos son útiles como agentes para tratar afecciones asociadas con trastornos relacionados con los huesos o anomalías esqueléticas causadas por el cáncer.
MX2019004862A 2016-10-28 2017-10-20 Anticuerpos anti-rankl y usos de los mismos. MX2019004862A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662414217P 2016-10-28 2016-10-28
PCT/US2017/057543 WO2018080914A1 (en) 2016-10-28 2017-10-20 Anti-rankl antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2019004862A true MX2019004862A (es) 2019-08-12

Family

ID=60191583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004862A MX2019004862A (es) 2016-10-28 2017-10-20 Anticuerpos anti-rankl y usos de los mismos.

Country Status (12)

Country Link
US (1) US10913799B2 (es)
EP (1) EP3532501A1 (es)
JP (3) JP7246306B2 (es)
KR (1) KR20190052137A (es)
CN (1) CN109890845B (es)
AU (1) AU2017351026A1 (es)
BR (1) BR112019006127A2 (es)
CA (1) CA3038850A1 (es)
EA (1) EA201990557A1 (es)
IL (1) IL266059A (es)
MX (1) MX2019004862A (es)
WO (1) WO2018080914A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3411066A1 (en) * 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US20030215450A1 (en) * 2000-05-26 2003-11-20 Blake Simon M Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
EP1458411A4 (en) 2000-08-21 2004-09-22 Smithkline Beecham Corp ANTI-RANK LIGAND MONOCLONAL ANTIBODIES SUITABLE FOR THE TREATMENT OF RANK LIGAND RELATED DISORDERS
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
JP2010524846A (ja) * 2007-03-20 2010-07-22 イーライ リリー アンド カンパニー 抗スクレロスチン抗体
WO2009105934A1 (zh) * 2008-02-27 2009-09-03 上海先导药业有限公司 抗人rankl单克隆抗体
AR073072A1 (es) * 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
CN105189551B (zh) * 2013-03-14 2021-03-05 埃派斯进有限公司 抗-rankl抗体及其使用方法
WO2015030701A1 (en) 2013-08-24 2015-03-05 R-Pharm Overseas, Inc. Fully human antibodies against human rankl
CN105085679B (zh) * 2014-04-25 2019-01-11 上海津曼特生物科技有限公司 全人源抗rankl抗体
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
CA2981115C (en) * 2015-05-18 2022-05-31 Eli Lilly And Company Anti-dkk-1-anti-rankl bispecific antibody compounds
EP3411066A1 (en) * 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds

Also Published As

Publication number Publication date
CN109890845A (zh) 2019-06-14
JP2024073462A (ja) 2024-05-29
WO2018080914A1 (en) 2018-05-03
JP7246306B2 (ja) 2023-03-27
JP2020500836A (ja) 2020-01-16
EA201990557A1 (ru) 2019-09-30
US20190284289A1 (en) 2019-09-19
JP2022058436A (ja) 2022-04-12
EP3532501A1 (en) 2019-09-04
US10913799B2 (en) 2021-02-09
CA3038850A1 (en) 2018-05-03
CN109890845B (zh) 2022-07-01
KR20190052137A (ko) 2019-05-15
IL266059A (en) 2019-06-30
BR112019006127A2 (pt) 2019-06-18
AU2017351026A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
NZ738008A (en) Tigit-binding agents and uses thereof
PH12017502013A1 (en) Anti-ox40 antibodies and methods of use thereof
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
PH12016502345A1 (en) Anti-gitr antibodies and methods of use thereof
EA201891983A8 (ru) Комбинированная терапия антителами к cd73
MX2020006668A (es) Anticuerpos para lilrb2.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
MA40074A (fr) Composés liant ras multivalents
GEP20227419B (en) Pd-1-binding molecules and methods of use thereof
EA201791093A1 (ru) Антитела к cd47, способы и применение
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
PH12016501366A1 (en) Novel anti-baff antibodies
EP3964527A3 (en) Combination therapy for cancer
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12016502607A1 (en) Functionalised and substituted indoles as anti-cancer agents
GEP20217271B (en) Combination therapy for the treatment of cancer
MY201478A (en) Antibodies and assays for detection of folate receptor 1
MY200162A (en) Anti-gitr antibodies and uses thereof
WO2017035430A3 (en) Anti-alk antibodies and methods for use thereof